Magrolimab

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer	2024/08/06	NCT06540261	Phase 1	Active, not recruiting	Ono Pharmaceutical Co. Ltd
An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer	2024/08/01	NCT06532344	Phase 1	Active, not recruiting	Ono Pharmaceutical Co. Ltd
Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma	2023/09/21	NCT06046482	Phase 2	Terminated	M.D. Anderson Cancer Center
An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma	2023/07/03	NCT05929716	Phase 2	Withdrawn	M.D. Anderson Cancer Center
A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)	2023/04/28	NCT05835011	Phase 2	Terminated	Astex Pharmaceuticals, Inc.
Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS	2023/04/25	NCT05829434	Phase 2	Withdrawn	Uwe Platzbecker
Magrolimab in Combination With Azacitidine After Allogeneic HCTin Treating Patients With High-Risk AML or MDS	2023/04/21	NCT05823480	Phase 1	Suspended	City of Hope Medical Center
Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial Carcinoma	2023/02/21	NCT05738161	Phase 1	Withdrawn	Insel Gruppe AG, University Hospital Bern
US Expanded Access Program for Magrolimab in Patients With Relapsed or Refractory Acute Myeloid Leukemia	2022/11/25	NCT05627466	N/A	NO_LONGER_AVAILABLE	Gilead Sciences
A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants	2022/05/10	NCT05367401	Phase 1	Withdrawn	Novartis Pharmaceuticals

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Related News

ALX Oncology's CD47 Inhibitor Combination with Keytruda Fails in Dual Phase II Trials

2 months ago

ALX Oncology reported that its CD47-blocking agent in combination with Merck's Keytruda (pembrolizumab) failed to meet primary endpoints in two separate Phase II clinical trials.

FDA Places Partial Clinical Hold on Gilead's Magrolimab Trials

5 months ago

The FDA has placed a partial clinical hold on trials of Gilead's magrolimab when used with azacitidine due to an imbalance in serious adverse events.

CD47 Expression Predicts Response to Magrolimab Plus Docetaxel in Metastatic NSCLC

8 months ago

Patients with mNSCLC treated with magrolimab plus docetaxel showed improved outcomes correlated with peripheral CD47 saturation, according to a phase 2 trial biomarker analysis.

CD47-Targeted Immunotherapies Show Promise in Cancer Treatment

10 months ago

CD47-targeted therapies are emerging as a novel cancer immunotherapy approach, inhibiting the "don't eat me" signal that cancer cells use to evade immune surveillance.

AI-Powered Research

Premium Access

Overview

Background

Indication

Associated Conditions